Medivir and SciLifeLab enter collaboration on potential SARS CoV-2 inhibitors
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered a research collaboration with the Drug Discovery and Development Platform (DDD) at SciLifeLab on potential inhibitors of SARS CoV-2. Through the collaboration, DDD will get access to Medivir’s unique proprietary protease-targeted compound library. The aim of the collaboration is to find potential inhibitors of the main protease of SARS CoV-2, an essential non-structural protein, M[pro], required for virus replication. DDD will mine the Medivir-developed unique protease-targeted compound library to